24th Int'l Prostate Cancer Update: Poster - Hematologic Safety of radium-223 dichloride (radium-223) in castration-resistant prostate cancer patients with bone metastases from the phase 3 ALSYMPCA trial: Baseline prognostic factor subgroup analysis

VAIL, CO USA (UroToday.com) - Presented by Joe M. O’Sullivan, Dimitris Voliotis, Dag Clement Johannessen, Anders Widmark, Isabel Syndikus, Nicholas James, Marcos Dall’Oglio, Ingvild Haugen, Andrew Cross, Jose Garcia- Vargas, and Nicholas Vogelzang at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

IPCU 2014 OSullivan thumb

Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, Northern Ireland;
Bayer HealthCare, Whippany, NJ, USA;
Ullevål University Hospital, Oslo, Norway;
Umeå University,Umeå, Sweden;
Clatterbridge Center for Oncology, Wirral, UK;
Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, Birmingham, UK;
Hospital das Clínicas, Faculdade de Medicina da USP, Instituto do Câncer do Estado de São Paulo, Brazil;
Algeta ASA, Oslo, Norway;
Sheffield Hallam University, Sheffield, UK;
Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
 

Click HERE to read the abstract from this session

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland